同义名 :	A-118; Mercarzole; U-32104; NSC 109874; Carbendazole
	CAS号 :	10605-21-7
	货号 :	A758150
	分子式 :	C9H9N3O2
	纯度 :	98%
	分子量 :	191.19
	MDL号 :	MFCD00055390
	存储条件：	Pure form Sealed in dry,2-8°C In solvent -20°C:3-6个月-80°C:12个月
	溶解度 :	-
	动物实验配方：

生物活性

描述

Carbendazim (CBZ) is a potent and orally active broad-spectrum benzimidazole fungicide and can be acts as a pesticide for fungal diseases research, such as Seproria, Fusarium and Sclerotina. Oral administrations with CBZ at 100 and 500 mg/kg body weight for 28 days induced hepatic lipid metabolism disorder which was characterized by significant increases of hepatic lipid accumulation and triglyceride (TG) levels in mice. Moreover, the increase in serum IL-1β and IL-6 levels by the treatment of CBZ indicated the occurring of inflammation[1]. All tested carbendazim and astaxanthin combinations increased the anti-proliferative effect of Carb treatment alone and increased the G2/M phase cell cycle arrest compared to the DMSO-treated control. Astaxanthin and carbendazim co-treatment enhances the anti-proliferative effect of carbendazim as a single agent, while alleviating the carbendazim treatment-associated ROS production in MCF-7 cells[2].

实验方案
	1mg	5mg	10mg
1 mM 5 mM 10 mM	5.23mL 1.05mL 0.52mL	26.15mL 5.23mL 2.62mL	52.30mL 10.46mL 5.23mL

参考文献
[1]Jin Y, Zeng Z, Wu Y, Zhang S, Fu Z. Oral Exposure of Mice to Carbendazim Induces Hepatic Lipid Metabolism Disorder and Gut Microbiota Dysbiosis. Toxicol Sci. 2015 Sep;147(1):116-26 [2]Atalay PB, Kuku G, Tuna BG. Effects of carbendazim and astaxanthin co-treatment on the proliferation of MCF-7 breast cancer cells. In Vitro Cell Dev Biol Anim. 2019 Feb;55(2):113-119